



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

March 31, 2006

Robert W. Pollock
Lachman Consultant Services, Inc.
1600 Stewart Ave
Westbury, New York 11590

Dear Mr. Pollock:

Your petition requesting the Food and Drug Administration to determine whether Risperdal M Tab (Risperidone) Orally Disintegrating Tablets, 3 mg and 4 mg (NDA No. 21-444), has been voluntarily withdrawn or withheld from sale for safety or efficacy reasons, was received by this office on 03/31/2006. It was assigned docket number 2006P-0147CP1 and it was filed on 03/31/2006. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Jennie C. Butler, Director
Division of Dockets Management
Office of Management Programs
Office of Management

2006P-0147

ACK 1